Lilly Ready For More Risk When It Comes To Early Deals

Chief Scientific Officer Dan Skovronsky has remit over business development at Eli Lilly, and he said the company is looking to do more deals, including higher-risk early stage molecules and new modalities, during an investor briefing in New York Dec. 19. The company also provided 2019 financial forecasts.

SC1812_NYC Stock-Exchange_545235262 _1200.jpg

Eli Lilly & Co. is looking to increase the pace of business development to build out its portfolio, Chief Scientific Officer Dan Skovronsky said during an investor briefing in New York Dec. 19. Skovronsky oversees business development since taking over as chief scientific officer and president of Lilly Research Labs in June, and he said there have been some changes to the company's business development strategy.

"Some of the changes that you've probably seen already [are] … just a higher pace of deals overall," he said....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.